latest posts
January 31, 2017
Improving drug discovery: the Human-On-Chip project
In our sector it is well known that the process of drug development takes on average 10-15 years to be completed, and it costs over $1 billion to finally launch a successful drug onto the market. Around 60-80% of drug discovery projects are unsuccessful: many drugs fail once they enter the clinical stages of the drug development process.   These f...
December 7, 2016
Are biosimilars the new generic drugs?
Biologics are, mostly, large proteins derived from living organisms or cells and manufactured through a highly complex biotechnological process. Although these drugs are very efficacious, their cost is a major issue for patients and reimbursement agencies. A biosimilar, is the alternative to the original biologic, which shares highly similar, but not identical...
October 31, 2016
Polypharmacology and drug drug interactions
In the context of current demographics, with the percentage of the population age 60+ increasing and set to reach 2 billion people by 2050, the concept of drug drug interactions has become a hot topic. The increase in life expectancy comes with some challenges, as for example polymedication for chronic diseases.  With up to 40% of over 65 year olds curren...
September 15, 2015
Active Learning: a new trend in virtual screening
Virtual screening (VS) is time and resource consuming. However, VS is nowadays usually preferred by experts over classic iterative molecular design, i.e. design, synthesis, and testing. How could computer-aided drug discovery (CADD) merge the two paradigms? The answer is Active Learning.   Active Learning is nothing more than iterative synthesize...
May 11, 2015
Molecular Modeling and the Synchrotron
Last week Intelligent Pharma was invited to visit ALBA, the synchrotron of Barcelona. We attended to a workshop about industrial applications of synchrotron light for pharmaceutical companies and we spend almost the full day there: not only attending to the talks, but also visiting the facilities. We (re)discovered, during the visit, the small a...